Psoriasis is a chronic autoinflammatory skin disease. Although interleukin-17, derived from lymphocytes, has been shown to be critical in psoriasis, the initiation and maintenance of chronic skin inflammation has not been well understood. IL-25 (also called IL-17E), another IL-17 family cytokine, is well known to regulate allergic responses and type 2 immunity.
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In Brief
The inflammatory mechanism of psoriasis remains incompletely understood. In this issue, Xu et al. identified IL-25 as a key pathogenic factor regulating the proliferation of keratinocytes and psoriasis development in an autocrine expression manner.
INTRODUCTION
Psoriasis, affecting approximately 2% of the global population (Bos and De Rie, 1999) , is characterized by epidermal hyperplasia, increased angiogenesis, and dermal infiltration of inflammatory cells (Monteleone et al., 2011) . Recently, the IL-23-IL-17 axis has been shown to play a pivotal role in psoriasis in both animal and human studies. Particularly, neutralizing IL-17 shows strong therapeutic effects in patients with psoriasis, and blocking IL-17RA, the common receptor for IL-17 family cytokines, is even more effective (Hueber et al., 2010; Leonardi et al., 2012; Papp et al., 2012) , suggesting the involvement of additional IL-17 cytokines. Despite the advancement in treating psoriasis, the cellular and molecular mechanisms underlying the initiation and maintenance of psoriasis remain unclear.
The IL-17 cytokine family includes six members: IL-17A (or IL-17), IL-17B, IL-17C, IL-17D, , and IL-17F (Dong, 2008) . Not only IL-17 but also IL-17F, IL-17C, and IL-25 required IL-17RA for signaling (Gaffen, 2009; Zepp et al., 2011) . Among these cytokines, IL-17A, IL-17C, and IL-17F are upregulated in psoriatic lesions and function to promote keratinocyte proliferation, cytokine and chemokine production, angiogenesis, and dermal infiltration of various inflammatory immune cells (Albanesi et al., 1999; Harper et al., 2009; Homey et al., 2000; Lai et al., 2012; Nograles et al., 2008) . However, the role of IL-25 (IL-17E) in psoriasis remains unknown.
IL-25 (IL-17E) is important in type 2 immune response because it activates the IL-17RA-IL-17RB complex in a variety of cell types, including epithelial cells and type II lymphocytes-T helper-2 (Th2) and ILC2 cells (Fort et al., 2001; Morita et al., 2013; Suzukawa et al., 2012) . Injection of IL-25 recombinant protein or transgenic overexpression of IL-25 results in multi-organ inflammation, characterized by elevated expression of IL-4, IL-5, and IL-13, inflammatory-cell infiltration, and epithelial-cell hyperplasia (Fort et al., 2001; Hurst et al., 2002; Kim et al., 2002; Nakae et al., 2002; Pan et al., 2001) . Conversely, Il25 À/À mice are resistant to allergic asthma but defective in clearance of worm infections that are accompanied by defects in type 2 cytokines (Fallon et al., 2006; Mchenga et al., 2008; Owyang et al., 2006) . Notably, Il25 À/À mice show increased susceptibility to experimental autoimmune encephalo-myelitis, possibly because of an antagonistic effect on the Th17 response (Kleinschek et al., 2007) . In skin, it has been suggested that IL-25-producing dendritic cells (DCs) could affect skin barrier function in patients with atopic dermatitis by inhibiting filaggrin synthesis (Hvid et al., 2011) . Although has been extensively investigated in multiple inflammatory diseases, including dermatitis, its role in psoriasis is unclear.
In the current study, we identified IL-17-regulated IL-25 expression in keratinocytes as an important player in the amplification of psoriasiform inflammation and revealed that IL-25 signaling in keratinocytes induces cell proliferation and production of various cytokines and chemokines in a STAT3-dependent manner.
RESULTS

IL-25 Is Critical in the Development of Psoriasis
We first examined the expression of IL-25 on skin biopsies from ten psoriasis patients. Compared to normal patients, patients with psoriasis had significantly increased IL25 mRNA in lesional skin ( Figure 1A) . Consistently, immunofluorescent staining showed that the amount of IL-25 was abundantly increased in epidermal keratinocytes of lesional skin but slightly increased in non-lesional skin, of psoriasis patients compared to normal patients ( Figure 1B) . Notably, both IL-25 and IL-17 were only detectable in leukocytes from psoriasis patients, but IL-25 was not co-expressed with IL-17 in the same cells (data not shown). Because imiquimod (IMQ) is commonly used for inducing a psoriasis-like inflammation, we also examined IL-25 expression in this model and found that both mRNA and protein of IL-25 were increased in the dorsal skin of an IMQ-induced psoriasislike mouse model ( Figures 1C and 1D) .
To assess the role of IL-25 in psoriasis, we injected recombinant mouse IL-25 (rIL-25) intradermally into the ear or dorsal skin of C57BL/6 mice. rIL-25 induced psoriasis-like pathology, including acanthosis, parakeratosis, the infiltration of inflammatory cells, and ear swelling ( Figures 1E-1G ) and increased expression of Il25 and its receptors Il17rb, Il17, and Il17c (Figure 1H ), although some other features, including pustule formation, were not obvious, suggesting that IL-25 injection did not result in full-blown psoriasis. However, when we conducted IL-25 injection experiments in Il17a À/À mice, we found that IL-17A was not required for IL-25-induced skin inflammation ( Figure S1 ). To further determine the potential role of IL-25 in psoriasis, we subjected Il25 À/À mice to the IMQ model. Compared to control mice, they exhibited greatly reduced epidermal acanthosis and dermal thickness and significantly decreased development of pustules ( Figure 2A and Figure S2A were greatly reduced in the dermal and epidermal layers (Figure 2B and Figures S2B and S2D) . The total numbers of infiltrating neutrophils (CD45 + CD3 À CD11b + Ly6G + ) were also reduced, although the percentages were increased in the absence of IL-25 ( Figure 2C and Figure S2C ). Figure S4A ). Similar to what was found in the Il25 À/À mice, lack of IL-25 in keratinocytes significantly reduced epidermal acanthosis, dermal thickness, and immune-cell infiltration in the dermal layer and dramatically decreased pustule formation (Figures 3A and 3B and Figures S4B and S4C) . The numbers and percentages of dendritic cells, neutrophils, and gd T cells were all lower in lesional skin of Il25 f/f K5 Cre mice than in the Il25 f/f group. Macrophages were also decreased in numbers but not percentages ( Figure 3C and Figures  S4D-S4F ). IL-17 is critical for host defense to infection of pathogens such as Staphylococcus aureus in skin (Archer et al., 2013) . In this model, the host resistance was not reduced in Il25
Cre mice compared to WT mice ( Figure 3D ). However, IL-25 and IL-17RB were upregulated after infection ( Figure S4G ). Although IL-25 deficiency reduced IL-4 and IL-5 expression, it did not affect the expression of the IL-17A-induced antimicrobial peptides, such as S100A8, S100A9, LCN2, REG3b, and CAMP ( Figure S4H ), important for bacterial clearance in humans and mice (Cho et al., 2010; Cho et al., 2001; Ong et al., 2002; Robinson et al., 2014 All the assays were repeated three times with consistent results. Scale bars represent 100 mm in (B) and (D) and 50 mm (zoom in) or 100 mm (zoom out) in (E) and (G). p values were determined by unpaired t test or two-way ANOVA. Data are the means ± SEM. All data are representative of two independent experiments. See also Figure S1 .
IL-25 Targets Non-Hemapoietic Cells in Psoriasis
IL-25 acts on both immune and non-immune cells through IL-17RB. IL-25 stimulation greatly augmented the expression of Il17rb and Il25 in primary keratinocytes in vitro ( Figure 4A ). When we applied the IMQ model in Il17rb À/À mice, the psoriasis pathology was greatly diminished in IMQ-induced Il17rb -/-mice ( Figure 4B ). In addition, the expression of IL-17RB and mRNA was greatly diminished in Il25 À/À mice ( Figures 4C and 4D ).
To further assess the target cells of IL-25 in a psoriasis model, we transfered bone marrow cells isolated from WT and Il17rb À/À mice into lethally irradiated WT or Il17rb À/À mice and subjected the recipient mice to IMQ-induced psoriasis 8 weeks later. Il17rb À/À recipient mice showed significantly alleviated psoriasis-like symptoms, independent of the genotypes of donor bone marrow cells ( Figure 4E ). Using CD45.1 and CD45.2 mice to assess the degree of chimerism, we observed that most hemapoietic cells in the skin were derived from a donor (data not shown). In addition, epidermal Langerhans cells, reported to be radiation resistant (Price et al., 2015) , did not express IL-17RB (data not shown). Together, our data demonstrate that IL-25 regulates psoriasis largely through targeting non-hematopoietic cells, most likely keratinocytes.
A B C Figure 2. IL-25 is Required for the Induction of Psoriasis Model
WT (n = 7) and Il25 À/À mice (n = 6) were subjected to IMQ-induced psoriasis-like inflammation, and sacrificed on day 3.5 after disease induction. 
IL-25 Induces Keratinocyte Proliferation and Expression of Pro-Inflammatory Genes
To determine the functional downstream targets of IL-25 in keratinocytes, we examined the mRNA profiles of primary murine keratinocytes treated with or without IL-25 in vitro in duplicates for 8 hr by RNA sequencing. Among the IL-25-induced genes, there were a number of chemokines and cytokines that attract or induce various psoriasis-related immune cells. These included CCL2, for recruiting monocytes, T cells, and dendritic cells; and CX3CL1, for recruiting monocytes and T cells. In addition, many IL-25-induced genes, including Ccl2 (Purwar et al., 2006; Shiao et al., 2013) , Fn1 (Adams and Watt, 1989; Bata-Csorgo et al., 1998; Wu et al., 2012) , and Bmp6 (D'Souza et al., 2001; Kaiser et al., 1998) , have been reported to regulate cell proliferation and cell-cycle progression ( Figure 5A ). Further, Ccl2 could also be upregulated by IL-17A stimulation, but IL-17A did not affect the expression of Bmp6, Fn1, Naip5, Cx3cl1, or Dclre1c ( Figure S5A ). Thus, IL-25 could regulate psoriasis development by regulating cell proliferation and pro-inflammatory gene induction. 
K5
Cre (n = 5) mice were infected with Staphylococcus aureus for 3 days, and the skin tissues at the infection site were used to measure the size of abscess and calculate the colony-forming unit (CFU). All the assays were repeated three times with consistent results. The scale bar represents 50 mm. p values were determined by unpaired t test. All data are representative of two independent experiments. See also Figure S4 .
To further assess this, we treated primary keratinocytes with IL-25 in vitro and found that IL-25 increased the number of viable keratinocytes in a dose-dependent manner ( Figure 5C ) and that there was a more pronounced effect at a later stage (Figure 5D ). Consistently, IL-25 also increased the expression of Ki67, a proliferation marker, and more cells entered active cell cycle (S and G2/M phase) (Figures 5E and 5F and Figure S5B ). Conversely, IL-25 deficiency significantly reduced the epidermal layer-associated Ki67 + ( Figure 5G and Figure S5C ) and BrdU 
Act1 and STAT3 are Required for IL-25-Mediated Function in Keratinocytes
Because the adaptor protein Act1 was previously shown to mediate IL-25 signaling (Kang et al., 2012; Swaidani et al., 2009) , we compared the expression of several IL-25-regulated genes associated with cell proliferation or inflammatory responses in keratinocytes from WT and Act1 À/À mice. Act1
completely abolished the effect of IL-25 treatment ( Figure 6A ). Moreover, as predicted, keratinocyte proliferation induced by IL-25 was found to depend on Act1 ( Figure 6B and Figure S6A ). STAT3 is known to control cell cycling and proliferation in many cell types, including keratinocytes, and has been shown to be involved in psoriasis-like skin inflammation (Sano et al., 2005) . To determine whether IL-25 regulates keratinocyte proliferation by activating STAT3, we examined STAT3 phosphorylation by phosphoflow in primary keratinocytes in vitro. The results showed that IL-25 stimulation resulted in apparent STAT3 phosphorylation at 24 hr ( Figure 6C and Figure S6B ). Consistently, skin injection of IL-25 also induced obvious STAT3 phosphorylation ( Figure 6D ). In addition, blocking STAT3 activation by a STAT3 inhibitor Sttatic significantly reduced IL-25-induced keratinocyte proliferation as determined by both cell-cycle analysis and Ki67 staining, which were independent of IL-6 ( Figure 6E and Figure S6C ). We also found that the expression of genes such as Ccl2 and Cx3cl1, which are related to keratinocyte proliferation and leukocyte recruitment, depended on STAT3, whereas expression of other genes, such as Naip5 and Dclre1c, was independent of STAT3 ( Figure 6F ).
IL-25-IL-17RB Activates the STAT3 Pathway
Our above data suggested that IL-25 might directly activate STAT3. We thus stimulated primary murine keratinocytes for a short time period and found that within 10 min after stimulation, IL-25 induced apparent STAT3 phosphorylation, which was dependent on Act1 but independent of IL-6 and was completely abolished by the JAK1&2 inhibitor treatment ( Figures 7A and 7B and Figure S7A ). STAT3 might be directly activated by IL-25. We then tested whether STAT3 associates with IL-17RB by performing an immunoprecipitation experiment with a HA-tagged IL-17RB expressed in HEK293T cells. We found that STAT3 was detected by immunoblotting from immunoprecipitated IL-17RB ( Figure 7C ). Moreover, IL-25 induced robust phosphorylation of IL-17RB at the tyrosine residue 10 min after treatment (Figure 7D) . Because it has been reported that the tyrosine residues Y444 and Y454, but not the other four sites within the IL-17RB, were required for the interaction of STAT5 and IL-17RB (Wu et al., 2015) , we next tested whether these two sites were also important for the binding of IL-17RB and STAT3. Immunoprecipitation results showed that IL-17RB-STAT3 association was decreased by mutation of the tyrosine residues Y444 and Y454 in IL-17RB ( Figure S7B ). Because IL-25 signals through the heterodimer receptor IL-17RA-IL-17RB complex (Angkasekwinai et al., 2010) , we then examined the interaction of IL-17RA-RB complex and STAT3 in primary murine keratinocytes upon IL-25 stimulation and found that endogenous IL-17RA was found to be co-precipitated with STAT3 ( Figure 7E ). Taken together, these findings indicate that IL-25 signaling can directly activate STAT3 phosphorylation in keratinocytes. Figure S5 . 
DISCUSSION
Despite recent success with targeting IL-17 or IL-23 in psoriasis, the mechanisms underlying initiation and maintenance of chronic inflammation in this disease are unclear. A recent study has shown elevated IL-25 expression in skin lesions of psoriasis; however, the protein's function was unclear (Sano et al., 2005) . Here we showed that IL-25 was highly expressed both in patients with psoriasis and in an IMQ-induced psoriasis mouse model ( Figures  1A-1D) . Importantly, germline deletion or selective keratinocytespecific ablation of Il25 greatly alleviated key features of psoriatic symptoms, including epidermal hyperplasia and scaly and dermal infiltration by immune cells, although it did not completely abolish the total psoriasiform skin inflammation, which was accompanied by decreased expression of key psoriasis-related cytokines. 2006 ; Wang et al., 2007) . In patients with psoriasis and in an IMQ-induced psoriasis mouse model, IL-25 expression was predominantly enriched at the epidermal layer of lesional skin, suggesting that keratinocytes could serve as the target cells of IL-25. Indeed, IL-25 stimulation not only augmented the expression of Il17rb on keratinocytes but also induced copious Il25 expression in primary keratinocytes, suggesting an autocrine regulation of IL-25. Moreover, IL-25 stimulation significantly promoted the expansion and cell-cycle progression of keratinocytes in vivo and in in vitro cultures, whereas IL-25 deficiency greatly impaired proliferation of keratinocytes and epidermal hyperplasia in a murine psoriasis model. These data support keratinocytes as the target of IL-25 in psoriasis. Consistently, when bone marrow transfer experiments were conducted, only Il17rb À/À recipient mice were resistant to induction of psoriatic skin inflammation, independent of donor cells received. This finding is not consistent with a recent study that indicated macrophages as the major target cells in psoriasis patients (Sano et al., 2005) . The role of IL-17RB in macrophages needs further investigation. STAT3 has been shown to play a critical role in regulating the proliferation of keratinocytes and psoriasis development, and keratinocyte-specific expression of the hyper-active form of STAT3 leads to spontaneous psoriasis-like inflammation (Sano et al., 2005) . Here, we found that IL-25-induced keratinocyte proliferation could be abolished in the presence of STAT3 inhibitor Stattic. Furthermore, IL-25 induced rapid STAT3 phosphorylation in primary keratinocytes as early as 10 min after stimulation, in an IL-6-independent and Act1-dependent manner. STAT3 could be co-immunoprecipitated not only with IL-17RB in an overexpression system but also with the endogenous IL-17RA in primary keratinocytes in response to IL-25, suggesting a direct role of IL-25 in activating STAT3. A recent study shows that IL-25 can directly activate STAT5 in T cells in an Act1-independent manner, suggesting that STAT family proteins might be involved in IL-25 signaling in a cell type-specific fashion (Wu et al., 2015) .
To further understand the function of IL-25 in keratinocytes and the pathogenic process of psoriasis, we examined the gene expression profile in keratinocytes stimulated with or without IL-25. Consistent with a critical role of IL-25 in dermal infiltration of various inflammatory cells, IL-25 stimulation induced a number of chemokines or cytokines regulating the migration or generation of inflammatory immune cells. For example, Ccl2, encoding the protein CCL2 (which is also known as MCP1 and is a downstream target of STAT3), has been shown to recruit memory T cells and DCs and promote skin inflammation (Purwar et al., 2006) ; Cx3cl1 plays a role in regulating the chemotaxis of monocytes or T cells. It is noted that IL-25 induced genes (including Naip5, Dclre1c, Cx3cl1, and Fn1) that were shown to play a positive role in regulating cell cycle progression and cell proliferation, whereas IL-25 downregulated genes such as Bmp6 that negatively regulate cell growth and cell cycling. In addition, Fn1, encoding fibronectin, and Ccl2 have been shown to inhibit the terminal differentiation of keratinocytes (BataCsorgo et al., 1998; Shiao et al., 2013; Wu et al., 2012) . Consistent with the dependence of IL-25 on Act1 and STAT3 in regulating the proliferation of keratinocytes, regulation of above genes by IL-25 was almost exclusively dependent on the presence of Act1, the downstream adaptor protein for IL-17RB signaling, but partially relied on the presence of STAT3.
Together, our findings suggest broad functions of IL-25 in shaping the pathogenic features in development of psoriatic skin inflammation through multiple mechanisms.
Although IL-25 is able to regulate its own expression in keratinocytes, it is barely expressed in normal healthy skin, suggesting the presence of additional factor(s) in triggering the initial expression of IL-25. Stimulation with IL-17, but not IL-17C, IL-1, or TNF-a, induced robust Il25 expression in primary murine keratinocytes in vitro, and Il17 À/À mice showed reduced IL-25 expression in lesional skin in the IMQ-induced psoriasis model. In addition, a subset of IL-25-regulated genes, including Il17c, Il6, and other genes, was also reported as downstream targets of IL-17 in psoriasis development, (Muromoto et al., 2016) . Considering the importance of IL-25 in regulating psoriasis-like skin inflammation, we thus highlight IL-25 as a critical functional downstream target of IL-17 in the development of psoriasis. On the other hand, Il17 expression was also decreased in Il25 À/À mice in the IMQ-induced psoriasis model, possibly as a result of reduced recruitment of IL-17-producing gd T cells, which are the major cell source of IL-17A in the development of psoriasiform skin inflammation . Thus, IL-25 is not only regulated by IL-17A but also might be required for optimal IL-17A production in the development of psoriasis. However, psoriatic inflammation induced by IL-25 injection was not affected in Il17a À/À mice, suggesting that IL-25 signaling in keratinocytes is independent of IL-17A. These results thus further highlight the importance of IL-25 in regulating psoriatic skin inflammation. In summary, our study has identified IL-25 to be critical in psoriatic skin inflammation. IL-25-IL-17RB presents itself as a keratinocyte autoregulatory circuit that amplifies and sustains chronic inflammation in psoriasis. IL-25 is not required for IL-17A-mediated host defense against bacterial infection, so targeting it might not have strong adverse effects in patients. Considering the high expression of IL-25 in patients with psoriasis and the effect of IL-25 blockade in a therapeutic chronic psoriasis-like mouse model, inhibiting IL-25 provides a novel therapeutic approach in the treatment of psoriasis.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: (genetically ablated mice), Il17 À/À and Act1 À/À mice are all C57BL/6 background and were described in the previous studies (Angkasekwinai et al., 2010; Chang et al., 2011; Martin-Orozco et al., 2009; Reynolds et al., 2015; Watarai et al., 2012) . Il17rb À/À mice were generated by replacement of Il17rb exon 1 with IRES-EGFP cassette using the 129-TC1 embryonic stem cell line. The targeting vector contained NeoR as a positive selection marker and the diphtheria toxin A (DTA) gene as a negative selection marker. Targeted ES clones were selected and injected into C57BL/6 blastocysts to generate chimeras. PCR genotyping was performed using primers as follows: forward, 5 0 -CTGCTCCAGTCAGCCTCTCT-3 0 ; reverse 1, 5 0 -AGCAGCTGGGCAAGTGAC-3 0 ; reverse 2, 5 0 -AGGTGGAGAAAGTGCCTGT-3 0 PCR produce a 435-bp WT allele and a 566-bp KO allele. The K5Cre transgenic mice were obtained from Xiao Yang lab in the Academy of Military Medical Sciences in China. All the mice were housed in the SPF animal facility at Tsinghua University. All the animal experiments were performed with the use of protocols approved by the Institutional Animal Care and Use Committee at Tsinghua University.
Bone Marrow Chimera Mice
The WT and Il17rb À/À recipient mice were first lethally irradiated (750Rads) and then reconstituted with 5x10 6 bone marrow cells isolated from either WT or Il17rb À/À donor mice. The recipient mice were subjected to imiquimod-induced psoriasis-like inflammations 8 weeks after bone marrow reconstitution, and analyzed as above descriptions. cryosectioned, blocked, and then stained with goat anti-mouse IL-25 antibody (Clone: M-15, Santa Cruz) and psoriasis patient skin paraffin sections were stained with anti-IL-25 (Clone:182203, R&D) and anti-IL-17A (H-132, Santa Cruz). For immunochemistry, the mouse skin paraffin sections were stained with anti-Ki67 (SP6, Abcam) and mouse monoclonal anti-BrdU antibody (Colon:BU-33, Sigma) t. The fluorescence image was taken with Nikon microscope, and analyzed by ImageJ Analysis software. The thickness of epidermis or dermis was calculated based on the total area versus the length of epidermis or dermis as described previously (Zheng et al., 2007) .
Immunoprecipitation HEK293T cells were cultured in completed DMEM medium, and transfected with 10 mg of HA-IL-17RB-PCDNA3.1, mutated IL-17RB-PCDNA3.1 and flag-STAT3-pMx, using Lipofectamine 2000. After IL-25 stimulation, cells were lysed with RIPA buffer (pH 7.4) (CWBIO, CW2334S) containing the protease inhibitor cocktail (Invitrogen). 15 mg of total protein was used for immunoprecipitation with mouse anti-HA antibody (Clone: 26D11, Abmart), and the precipitated protein complex was used for immunoblotting with antibodies against pSTAT3 (Clone: D3A7, CST), STAT3 (Clone: H-190, Santa Cruz), Actin (Clone: 1C7, Abbkine), pTyr (Clone: 4G10, Millipore), HA-tag (Clone:2B11, Easybio) and Flag-tag (Clone: 3C6, Easybio).
Skin Staphylococcus aureus Infection Model
Staphylococcus aureus Newman was cultured in Brain-Heart Infusion (BHI) broth at 37 C to log phase and then stored in 15% glycerol at À80
C for 2 days. The bacterial number in glycerol stock was counted by serially dilution on Tryptic Soy Agar (TSA) plates. For infection, bacteria were centrifuged and resuspended in Ringer's solution. f/f and IL-25 f/f K5 Cre mice were shaved and intradermally injected with 5 3 10 7 CFU in 50 mL Ringer's solution. 3 days after infection, skin tissues were collected for bacterial counting and immune analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical Analysis
The data were analyzed by Graph Prism 6.0 software, and the statistics were analyzed by unpaired Student's t test or one-way or two-way ANOVA. P values were provided as * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001.
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